1-7 of 7
Apurvasena Parikh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response Analyses Supporting Optimal Epcoritamab Full Dose and Dosing Schedule in Relapsed or Refractory Follicular Lymphoma

Free
Mahipal Gurram Sinnollareddy, Leonid Gibiansky, Kinjal Sanghavi, Steven Xu, Mohamed-Eslam F Mohamed, Poliana P. Patah, Elena Favaro, Manish Gupta, Apurvasena Parikh, Tommy Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 1414.
https://doi.org/10.1182/blood-2024-197962
Published: 2024
Journal Articles

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Free
Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Marcel van der Linden, Kinjal Sanghavi, Matthew Putnins, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4481.
https://doi.org/10.1182/blood-2023-179555
Published: 2023
Journal Articles

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Free
Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Christopher W. Chiu, Mariana Sacchi, Huaibao Feng, Tahi Ahmadi, Manish Gupta, Steven Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3135.
https://doi.org/10.1182/blood-2023-181322
Published: 2023
Journal Articles

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Free
Laurie H. Sehn, Johannes Duell, Irit Avivi, Joshua Brody, Dok Hyun Yoon, Brian Elliot, Satya R. Siddani, Yang Bai, Apurvasena Parikh, Mostafa M. Seliem, Minh Dinh, Alan P. Skarbnik
Journal: Blood
Blood (2022) 140 (Supplement 1): 12108–12109.
https://doi.org/10.1182/blood-2022-157596
Published: 2022
Journal Articles

Phase 1b Trial of Subcutaneous Epcoritamab in Pediatric Patients with Relapsed or Refractory (R/R) Aggressive Mature B-Cell Neoplasms (EPCORE Peds-1)

Free
Mitchell S. Cairo, Mark A. Rocco, John Bernard, Satya R. Siddani, Apurvasena Parikh, Brian Elliott, Birgit Burkhardt
Journal: Blood
Blood (2022) 140 (Supplement 1): 3827–3828.
https://doi.org/10.1182/blood-2022-157546
Published: 2022
Journal Articles

Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-Cell Non-Hodgkin's Lymphoma (NHL)

Free
PK Epling-Burnette, Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Elke Gresnigt - van den Heuvel, Apurvasena Parikh, Tommy Li, Christopher W Chiu, Adam Chervin, Edward B Reilly, Edith Szafer-Glusman
Journal: Blood
Blood (2022) 140 (Supplement 1): 9283–9285.
https://doi.org/10.1182/blood-2022-162538
Published: 2022
Journal Articles

Novel Structurally-Modified Allosteric Effectors of Hemoglobin Exhibit Superior Antisickling Properties

Free
Osheiza Abdulmalik, DVM, MS, Tanvi Deshpande, MS, Mohini Ghatge, PhD, Yan Zhang, PhD, Jurgen Venitz, MDPhD, Apurvasena Parikh, PhD, Martin K. Safo, PhD
Journal: Blood
Blood (2014) 124 (21): 218.
https://doi.org/10.1182/blood.V124.21.218.218
Published: 2014